Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Active, not recruiting · NCT05999604 · Registry updated 2026-08-28

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 3	2026-08-28		NCT05999604

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fondation Ophtalmologique Adolphe de Rothschild	81

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
CH Gonesse	Gonesse	France	2
CHI Poissy-Saint-Germain en Laye	Poissy	France	1
CHU de Grenoble	Grenoble	France	22
CHU de Limoges	Limoges	France	24
CHU de Nice	Nice	France	21
CHU de Strasbourg	Strasbourg	France	2
Fondation Adolphe de Rothschild	Paris	France	8
Hôpital de la Pitié-Salpêtrière	Paris	France	6
Hôpital Foch	Suresnes	France	43
Hôpital Henri Mondor	Créteil	France	13
Hôpital Pierre Wertheimer (HCL)	Lyon	France	1